---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-101093"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2021-08-06T23:59:59+00:00"
generated_at: "2026-06-29T20:27:57.054406+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q3 revenue $35M (+65% YoY); raises FY2021 guidance

## Summary
- Revenue $35.0M vs $21.2M YoY; orders $39.1M (+58% YoY).
- Net loss $40.0M ($0.82/share) vs $28.2M ($0.67) YoY.
- Gross margin 40%; cash $519.4M; raising FY2021 revenue guidance.
- Shipped 107,000 genes (vs 83,000 YoY); acquired iGenomX for NGS tools.
- Began shipping synthetic SARS-CoV-2 Delta RNA controls; appointed Dr. Melissa Starovasnik to board.

## SEC filing metadata
- accession: 0001104659-21-101093
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2021-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000110465921101093/0001104659-21-101093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000110465921101093/tm2123937d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-101093
- JSON: https://secwatch.observer/filing/0001104659-21-101093.json
- Plain text: https://secwatch.observer/filing/0001104659-21-101093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.